2023 World Conference on Lung Cancer (Posters)-P2.05. Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study

P2.05. Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study - PDF(Abstract)

Back to course

Pdf Summary

A multicenter prospective study evaluated the impact of thyroid transcription factor-1 (TTF-1) expression on the efficacy of combined chemoimmunotherapy in advanced lung adenocarcinoma patients. 58 patients who had not previously undergone chemotherapy or immunotherapy were included in the study. TTF-1 expression was evaluated through immunohistochemical analysis and patients were grouped as TTF-1 positive or negative. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and objective response rate (ORR).<br />The results showed that the TTF-1 positive group had a significantly longer PFS and OS than the TTF-1 negative group. The objective response rate (ORR) and disease control rate (DCR) were also higher in the TTF-1 positive group. The TTF-1 positive group had a significantly higher PD-L1 expression than the TTF-1 negative group. Multivariate analyses revealed that TTF-1 positivity and PD-L1 TPS ≥ 50% were independent predictive factors for prolonged PFS.<br />Overall, the study findings suggest that TTF-1 and PD-L1 are predictive factors for the clinical outcome of combined chemoimmunotherapy in lung adenocarcinoma patients. These findings could potentially aid in making more informed treatment decisions in the future.

Asset Subtitle

Yuki Katayama

Meta Tag

Speaker Yuki Katayama

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

multicenter study

TTF-1 expression

chemoimmunotherapy

lung adenocarcinoma

progression-free survival

overall survival

objective response rate

PD-L1 expression

predictive factors

treatment decisions